-+ 0.00%
-+ 0.00%
-+ 0.00%

Passage Bio Falls Short of Nasdaq Minimum Stockholders' Equity Requirement

PUBT·11/18/2026 21:20:11
Passage Bio Falls Short of Nasdaq Minimum Stockholders' Equity Requirement
  • Passage Bio received a Nasdaq noncompliance notice on November 12, 2026, for failing to meet the minimum stockholders' equity requirement.
  • Stockholders' equity totaled $50,000 as of September 30, 2026, below Nasdaq Capital Market's $2.5 million minimum.
  • The notice has no immediate effect on its common stock listing on the Nasdaq Capital Market.
  • The company expects its planned mergers with Remix Therapeutics to restore compliance, with closing subject to Nasdaq listing approval.
  • If the mergers miss Nasdaq's permitted compliance period, the company intends to submit a plan to regain compliance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-044734), on November 18, 2026, and is solely responsible for the information contained therein.